Cargando…
Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts
PURPOSE: Prostate cancer is multifocal. However, there often exists a single dominant focus in the gland responsible for driving the biology of the disease. Dose escalation to the dominant lesion is a proposed strategy to increase tumor control. We applied radiobiological modeling to evaluate the do...
Autores principales: | Goodman, Christopher D., Fakir, Hatim, Pautler, Stephen, Chin, Joseph, Bauman, Glenn S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136625/ https://www.ncbi.nlm.nih.gov/pubmed/32280821 http://dx.doi.org/10.1016/j.adro.2019.09.004 |
Ejemplares similares
-
Dosimetric Uncertainties in Dominant Intraprostatic Lesion Simultaneous Boost Using Intensity Modulated Proton Therapy
por: Zhou, Jun, et al.
Publicado: (2021) -
Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour
por: Gaudreault, Mathieu, et al.
Publicado: (2022) -
PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
por: Ramnaraign, Brian, et al.
Publicado: (2023) -
Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial
por: McDonald, Andrew M., et al.
Publicado: (2018) -
Ten-Year Results From a Phase II Study on Image Guided, Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in High-Risk Prostate Cancer
por: Ekanger, Christian, et al.
Publicado: (2019)